• Publications
  • Influence
Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy
We describe that galectin-1 (gal-1) is a receptor for the angiogenesis inhibitor anginex, and that the protein is crucial for tumor angiogenesis. gal-1 is overexpressed in endothelial cells ofExpand
Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells
The anti-cancer effects of metformin, the most widely used drug for type 2 diabetes, alone or in combination with ionizing radiation were studied with MCF-7 human breast cancer cells and FSaII mouse fibrosarcoma cells, finding it was preferentially cytotoxic to cancer stem cells relative to non-cancer stem cells. Expand
Scheduling of Radiation with Angiogenesis Inhibitors Anginex and Avastin Improves Therapeutic Outcome via Vessel Normalization
The oxygen elevation in tumors by non–growth factor–mediated peptide anginex suggests that vessel normalization might be a general phenomenon of agents directed at disrupting the tumor vasculature by a variety of mechanisms. Expand
Epigenetic regulation of tumor endothelial cell anergy: silencing of intercellular adhesion molecule-1 by histone modifications.
The data show that ICAM-1 is epigenetically silenced in tumor endothelial cells by promoter histone modifications, which can be overcome by DNMT and HDAC inhibitors, suggesting a new molecular mechanism based on which novel therapeutic approaches for cancer can be pursued. Expand
Microbeam Radiation Therapy Alters Vascular Architecture and Tumor Oxygenation and is Enhanced by a Galectin-1 Targeted Anti-Angiogenic Peptide
The results suggest that tumor vascular damage induced by MRT at these potentially clinically acceptable peak entrance doses may provoke vascular normalization and may be exploited to improve tumor control using agents targeting angiogenesis. Expand
Anti‐angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte‐endothelium interactions and infiltration in tumors
The new angiostatic designer peptide anginex was most potent at overcoming EC anergy; the enhanced leukocyte‐vessel interactions led to an increase in the numbers of tumor infiltrating leukocytes, and the current results suggest that immunotherapy strategies can be improved by combination with anti‐angiogenesis. Expand
Design of nonpeptidic topomimetics of antiangiogenic proteins with antitumor activities.
The results demonstrate the feasibility of designing nonpeptidic, calixarene-based protein surface topomimetics as novel pharmaceutical agents for clinical intervention against cancer through angiostatic or other mechanisms. Expand
Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature.
The results demonstrate the usefulness of the identification and subsequent targeting of specific tumor endothelial markers for anticancer therapy and inhibit tumor growth and reduced microvessel density in a mouse tumor model. Expand
The designed angiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin.
Assessment of microvessel density suggested that the antitumor activity of anginex is mediated by angiogenesis inhibition, and the ability to improve conventional chemotherapy and antiangiogenesis therapy was tested. Expand
Anginex synergizes with radiation therapy to inhibit tumor growth by radiosensitizing endothelial cells
Investigation of the effect of anginex on established tumor vasculature as an adjuvant to radiation therapy of solid tumors supports the idea that the combination of the antiangiogenic agentAnginex and radiation may lead to improved clinical outcome in treating cancer patients. Expand